SK bioscience Co.,Ltd. (KRX:302440)

South Korea flag South Korea · Delayed Price · Currency is KRW
46,725
-2,225 (-4.55%)
Last updated: Mar 3, 2026, 2:35 PM KST
9.81%
Market Cap 3.84T
Revenue (ttm) 624.03B
Net Income (ttm) -5.90B
Shares Out 78.43M
EPS (ttm) -75.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 207,285
Average Volume 161,851
Open 47,950
Previous Close 48,950
Day's Range 46,650 - 48,300
52-Week Range 35,800 - 61,300
Beta 1.09
RSI 33.17
Earnings Date Feb 3, 2026

About SK bioscience

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical tr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 917
Stock Exchange Korea Stock Exchange
Ticker Symbol 302440
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.